KLANG: About nine bus loads of medical glove manufacturer Top Glove Corp Bhd’s workers were whisked away by the Health Department Monday (Nov 23) night.

Although the exact numbers are yet to be known, it is believed that slightly more than 360 workers were taken away to the Sungai Buluh and Kuala Lumpur Hospitals to be treated for Covid-19.

16 factories already stopped operation and 12 factories operating at much reduced capacities (<50% capacity) since 1 week ago (18 Nov).It will take at least 4 weeks for all the factories operating at full capacity.

Top Glove share price will test limit down price tomorrow and very weak sentiment.Limit down price tomorrow is RM6.25

With reference to the announcement by the Senior Minister today, Top Glove will work closely and cooperate fully with the relevant authorities to implement the temporary stoppage by stages of our manufacturing facilities in Meru, Klang.

Since 18 November 2020 until now, we have temporarily stopped production in 16 facilities in Meru, Klang. Balance 12 facilities in Meru, Klang have been operating at much reduced capacities.

With reference to the announcement by the Senior Minister today, Top Glove will work closely and cooperate fully with the relevant authorities to implement the temporary stoppage by stages of our manufacturing facilities in Meru, Klang.



Since 18 November 2020 until now, we have temporarily stopped production in 16 facilities in Meru, Klang. Balance 12 facilities in Meru, Klang have been operating at much reduced capacities.



With guidance from Kementerian Kesihatan Malaysia (KKM), we have completed full screening of about 5,700 workers at our hostels. We are committed to proceed with the KKM recommended COVID-19 screening test of the balance workers and staff of our factories in Meru, Klang.

28 out of 41 factories (70%)closed in stages and more than 2,000 workers positive Covid-19 as of today.Next 1-2 weeks another few thousand workers will test positive.

Closing Top Glove factories will increase ASP price further super normal profits for other top 3 glove companies Supermax,Hartalega and Kossan

KUALA LUMPUR: A total of 28 Top Glove factories in Klang, Selangor will cease operations in stages, said Senior Minister of Security Ismail Sabri Yaakob today.

Speaking at a press conference today, Ismail said the closure was to allow factory workers to undergo screenings and mandatory quarantine, in an effort to contain the spread of the virus among Top Glove employees.

“I am made to understand for today, there are 1,067 positive cases. On the advice of the health ministry, today’s meeting has agreed to close these factories in stages,” he said.

Closing Top Glove factories will increase ASP price further more profits for other top 3 glove companies Supermax,Hartalega and Kossan

Sinovac Biotech's experimental Covid-19 vaccine CoronaVac triggered a quick immune response preliminary trial results showed on Wednesday.

Researchers said it could provide sufficient protection, based on their experience with other vaccines and data from preclinical studies with macaques.

"Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation by giving two doses of the vaccine at a 14-day interval," Zhu Fengcai, one of the authors of the paper, said.

"We believe that this makes the vaccine suitable for emergency use during the pandemic," Zhu said in a statement published alongside the paper.

Gang Zeng, a Sinovac researcher involved in the CoronaVac study, said the vaccine could be an attractive option because it can be stored at normal fridge temperatures of 2 to 8 degrees Celsius (36-46F) and may remain stable for up to three years.

"(It) would offer some advantages for distribution to regions where access to refrigeration is challenging," the author said.

By contrast, vaccines developed by Pfizer/BioNTech and Moderna use a new technology called synthetic messenger RNA (mRNA) to activate the immune system against the virus and require far colder storage.

Sinovac Biotech's experimental Covid-19 vaccine CoronaVac triggered a quick immune response preliminary trial results showed on Wednesday.

Researchers said it could provide sufficient protection, based on their experience with other vaccines and data from preclinical studies with macaques.

"Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation by giving two doses of the vaccine at a 14-day interval," Zhu Fengcai, one of the authors of the paper, said.

"We believe that this makes the vaccine suitable for emergency use during the pandemic," Zhu said in a statement published alongside the paper.

Gang Zeng, a Sinovac researcher involved in the CoronaVac study, said the vaccine could be an attractive option because it can be stored at normal fridge temperatures of 2 to 8 degrees Celsius (36-46F) and may remain stable for up to three years.

"(It) would offer some advantages for distribution to regions where access to refrigeration is challenging," the author said.

By contrast, vaccines developed by Pfizer/BioNTech and Moderna use a new technology called synthetic messenger RNA (mRNA) to activate the immune system against the virus and require far colder storage.

KUALA LUMPUR (Nov 17): With 14-day Enhanced Movement Control Order (EMCO) placed on its foreign workers' dormitories in Meru, Klang, the world's largest rubber glove manufacturer Top Glove Corp Bhd has said it affects about 5,700 of its workers.

Top Glove clarified that the EMCO, which takes place from today until Nov 30, impacts about 27% of its total workforce of 21,000, according to a statement today.

"Our factories in Meru, Klang continue to operate with reduced capacity and workers not under EMCO are working under strict SOPs (standard operating procedures) in alignment with guidelines from the Ministry of Health," said Top Glove.

Sinovax and Sinopharm vaccines from China phase 3 excellent results release coming tis week/next week.

Sinovax and Sinopharm vaccines from China phase 3 excellent results release coming tis week/next week.

FDA approval for Pfizer vaccine coming tis week and Moderna vaccine next week.

FDA approval for Pfizer vaccine coming tis week and Moderna vaccine next week.

The Moderna vaccine is 94.5% effective against coronavirus, according to early data released Monday by the company, making it the second vaccine in the United States to have a stunningly high success rate.

"These are obviously very exciting results," said Dr. Anthony Fauci, the nation's top infectious disease doctor. "It's just as good as it gets -- 94.5% is truly outstanding."

Vaccinations could begin in the second half of December, Fauci said.

The Moderna vaccine is 94.5% effective against coronavirus, according to early data released Monday by the company, making it the second vaccine in the United States to have a stunningly high success rate.

"These are obviously very exciting results," said Dr. Anthony Fauci, the nation's top infectious disease doctor. "It's just as good as it gets -- 94.5% is truly outstanding."

Vaccinations could begin in the second half of December, Fauci said.

Moderna said Monday that early analysis from its Phase 3 trial shows its Covid-19 vaccine is 94.5 percent effective at preventing the illness, offering hope of a second breakthrough in as many weeks.

Fauci added that the vaccine seems to have been equally effective among a variety of participants. The phase 3 trial enrolled more than 30,000 participants in the United States, including people over 65 with high-risk conditions and from communities of color.

Moderna said its vaccine is expected to remain stable at standard refrigerator temperatures of 36 to 46 degrees Fahrenheit for 30 days, up from the previous estimate of seven days. The vaccine can remain stable at minus-4 degrees Fahrenheit for up to six months and at room temperature for 24 hours, the company said.

"These are temperatures commonly found in readily available pharmaceutical freezers and refrigerators which would enable simpler distribution in the United States and other parts of the world," the company said in a statement.

By year's end, it expects to have 20 million doses of the vaccine ready to ship in the U.S., and it remains on track to manufacture 500 million to 1 billion doses globally next year.

Moderna said Monday that early analysis from its Phase 3 trial shows its Covid-19 vaccine is 94.5 percent effective at preventing the illness, offering hope of a second breakthrough in as many weeks.

Fauci added that the vaccine seems to have been equally effective among a variety of participants. The phase 3 trial enrolled more than 30,000 participants in the United States, including people over 65 with high-risk conditions and from communities of color.

Moderna said its vaccine is expected to remain stable at standard refrigerator temperatures of 36 to 46 degrees Fahrenheit for 30 days, up from the previous estimate of seven days. The vaccine can remain stable at minus-4 degrees Fahrenheit for up to six months and at room temperature for 24 hours, the company said.

"These are temperatures commonly found in readily available pharmaceutical freezers and refrigerators which would enable simpler distribution in the United States and other parts of the world," the company said in a statement.

By year's end, it expects to have 20 million doses of the vaccine ready to ship in the U.S., and it remains on track to manufacture 500 million to 1 billion doses globally next year.

The U.S. Food and Drug Administration will move “as quickly as possible” to clear Pfizer and Moderna’s coronavirus vaccines for emergency use, the top official at the U.S. Department of Health and Human Services said Monday.

HHS Secretary Alex Azar told CNBC’s “Squawk Box” that the “incredible” interim results from Moderna, which announced on Monday that its vaccine candidate is more than 94% effective in preventing Covid-19, paired with similar results from Pfizer last week make for a “historic day in public health.”

Azar, who heads the federal agency that oversees the FDA, said it has dedicated teams working with both companies to “remove any unnecessary bureaucratic barriers” and are completing their authorization applications “as we speak.”

The U.S. Food and Drug Administration will move “as quickly as possible” to clear Pfizer and Moderna’s coronavirus vaccines for emergency use, the top official at the U.S. Department of Health and Human Services said Monday.

HHS Secretary Alex Azar told CNBC’s “Squawk Box” that the “incredible” interim results from Moderna, which announced on Monday that its vaccine candidate is more than 94% effective in preventing Covid-19, paired with similar results from Pfizer last week make for a “historic day in public health.”

Azar, who heads the federal agency that oversees the FDA, said it has dedicated teams working with both companies to “remove any unnecessary bureaucratic barriers” and are completing their authorization applications “as we speak.”

Dr. Anthony Fauci, the nation's top infectious disease expert, is hailing new data on Moderna's COVID-19 vaccine candidate as "striking" and "quite impressive."

Moderna revealed on Monday that preliminary phase-three data on its coronavirus vaccine suggested that it's 94.5 percent effective. This is a far better efficacy rate than experts had been anticipating in a vaccine against COVID-19, and it comes after Pfizer recently said its COVID-19 vaccine candidate also appears to be more than 90 percent effective.

"These are obviously very exciting results," Fauci told CNN on Monday. "It's just as good as it gets — 94.5 percent is truly outstanding."

Fauci, who previously said he would "settle" for a COVID-19 vaccine that's around 70 percent effective, also told NBC's Today the data is "quite impressive," adding that after last week's news from Pfizer, "Now we have two vaccines that are really quite effective, so I think this is a really strong step forward to where we want to be."

Dr. Anthony Fauci, the nation's top infectious disease expert, is hailing new data on Moderna's COVID-19 vaccine candidate as "striking" and "quite impressive."

Moderna revealed on Monday that preliminary phase-three data on its coronavirus vaccine suggested that it's 94.5 percent effective. This is a far better efficacy rate than experts had been anticipating in a vaccine against COVID-19, and it comes after Pfizer recently said its COVID-19 vaccine candidate also appears to be more than 90 percent effective.

"These are obviously very exciting results," Fauci told CNN on Monday. "It's just as good as it gets — 94.5 percent is truly outstanding."

Fauci, who previously said he would "settle" for a COVID-19 vaccine that's around 70 percent effective, also told NBC's Today the data is "quite impressive," adding that after last week's news from Pfizer, "Now we have two vaccines that are really quite effective, so I think this is a really strong step forward to where we want to be."

Britain expects to start rolling out the Pfizer COVID-19 vaccine just before Christmas if it is declared safe and effective, health minister Matt Hancock said on Monday.

"We're working very closely with the company," he told BBC TV. "We'll be ready to roll it out as soon as it comes, we'll be ready from the first of December..., but more likely is that we may be able to start rolling it out before Christmas."

Britain expects to start rolling out the Pfizer COVID-19 vaccine just before Christmas if it is declared safe and effective, health minister Matt Hancock said on Monday.

"We're working very closely with the company," he told BBC TV. "We'll be ready to roll it out as soon as it comes, we'll be ready from the first of December..., but more likely is that we may be able to start rolling it out before Christmas."

Top Glove 1st QR is from Sept to Nov.

Sinovac and Sinopharm vaccines excellent results coming few days

Sinovac and Sinopharm vaccines excellent results coming few days

Top Glove share price will drop below 6.20 tomorrow

Tomorrow Supermax share price will drops below RM7

Top Glove 13,190 workers out of total 21,000 workers which is 60% total workforce under quarantine for 2 weeks until 30 November.

Top Glove 13,190 workers out of total 21,000 workers which is 60% total workforce under quarantine for 2 weeks until 30 November.

Top Glove total staffs 21,000 and 13,000 staffs under quarantine for 2 weeks until 30 November.This indicates only 8,000 staffs (40%) able going to work.

Tomorrow opening price definitely gap down at least 50sen around 6.70

Tomorrow opening price definitely gap down 50-60 sen around 7.40-7.50

Pfizer’s vaccine, developed in collaboration with Germany’s BioNTech SE, has “an extraordinarily high degree of efficacy — more than 90%, close to 95%,” Fauci said in an interview. That could be a key factor in overcoming reluctance to take pandemic vaccines that have been developed at top speed.

Results of a late-stage trial of a vaccine candidate from Moderna Inc that uses the same messenger RNA technology as the Pfizer shot are likely to be available within a week, Fauci said. “And if that is really comparable to what we saw with the Pfizer trial, we’ll now have two highly effective vaccines,” he said

Post removed.Why?

Post removed.Why?

After Pfizer, another US drugmaker, Moderna Inc, is likely to release first interim analysis data on late-stage trials of its Covid-19 vaccine candidate. Experts have said that Moderna’s candidate, which uses a similar mRNA technology like Pfizer’s, will also likely prove to be highly effective.

After Pfizer, another US drugmaker, Moderna Inc, is likely to release first interim analysis data on late-stage trials of its Covid-19 vaccine candidate. Experts have said that Moderna’s candidate, which uses a similar mRNA technology like Pfizer’s, will also likely prove to be highly effective.

Another price gap down expected coming these few days as Moderna vaccine result release tis week and Sinovax and Sinopharm vaccine result release tis week/next week

Another price gap down expected coming these few days as Moderna vaccine result release tis week and Sinovax and Sinopharm vaccine result release tis week/next week

Weak market sentiment expected for Top Glove share price as Moderna,Sinopharm and Sinovax excellent phase 3 results coming out these few days and Pfizer submission to FDA for approval tis week 3rd of November

Weak market sentiment expected for Supermax share price as Moderna,Sinopharm and Sinovax excellent phase 3 results coming out these few days and Pfizer submission to FDA for approval tis week 3rd of November

Sinovac and Sinopharm vaccines phase 3 excellent results out this coming 1-2 weeks.Storage normal vaccine fridge no need ultra freezer -70 Celcius

Sinovac and Sinopharm vaccines phase 3 excellent results out this coming 1-2 weeks.Storage normal vaccine fridge no need ultra freezer -70 Celcius

Pfizer vaccine submission to FDA for approval 3rd week of November which is this week coming few days.

Market sentiment will push down price more as Moderna vaccine result out tis week.Sinovac and Sinopharm vaccine excellent result out within 1-2 weeks.

Market sentiment will push down price more as Moderna vaccine result out tis week.Sinovac and Sinopharm vaccine excellent result out within 1-2 weeks.